Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA granted priority review for the new drug application for Yondelis (trabectedin) to treat patients with advanced soft-tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy, including an anthracycline.